Claim 39 (newly added). A method according to Claim 31 wherein said biological response modifier comprises interferon.

Claim 40 (newly added). A method according to Claim 31 wherein said antibody comprises at least one of edrecolomab and antibodies against the EGFr, HER2 receptor or VEGF receptor, or any combination thereof.

Claim 41 (newly added). A method according to Claim 31 wherein said anti-hormone comprises tamoxifen.

REMARKS

Original claims 1-9 have been cancelled and replaced by claims 10-41, which correspond to claims that were cancelled from the parent application when it was allowed.

The specification has been amended to add an Abstract, as provided under 37 C.F.R. § 1.72(b).

New Claims 10-41 are being added herein. Support for the added claims is found throughout the specification and claims as filed do not represent new matter.

.

Peter David DAVIS U.S. Application No. 09/889,061

Applicant's undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 625-3500. All correspondence should be directed to our address given below.

AUTHORIZATION

Applicant believes there are no additional fees due in connection with this filing. However, to the extent required, the Commissioner is hereby authorized to charge any fees due in connection with this filing to Deposit Account 50-1710 or credit any overpayment to same.

Respectfully submitted,

Gilberto M. Villacorta, PH.D.

Registration No. 34,038

Robert W. Hahl, Ph.D.

Registration No. 33,893

Patent Administrator KATTEN MUCHIN ZAVIS ROSENMAN 525 West Monroe Street, Suite 1600 Chicago, Illinois 60661-3693 Facsimile: (312) 902-1061

Dated: July 3, 2003

EXHIBIT A

MARKED-UP VERSION OF THE SPECIFICATION SHOWING CHANGES

Beginning at page 25:

ABSTRACT

Vascular damaging agents composed of substituted 5(6)-substituted benzimidazole-2-carbamates are provided. These agents are useful in the preparation of medicaments for the treatment of diseases involving neovascularisation, particularly for the treatment of solid tumors, macular degeneration, diabetic retinopathy, rheumatoid arthritis, psoriasis, and atherosclerosis.

Embodiments include a 5(6)-substituted benzimidazole-2-carbamate of formula I

wherein A represents a multi-substituted alkyl group or aromatic ring.

EXHIBIT B

MARKED-UP VERSION OF THE CLAIMS SHOWING CHANGES

Claims 1-9. Cancelled.

Claims 10 - 41 (New)